Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Nutraceuticals Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Nutraceuticals Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ChromaDex's NRC Gets FDA ODD and RPD for Ataxia Telangiectasia
Details : Niagen (nicotinamide riboside chloride) is an oral supplement which significantly increases NAD+ levels, it is being investigated in Ataxia Telangiectasia.
Product Name : Niagen
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 06, 2024
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Charite University, Berlin, Germany
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
August 22, 2023
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Charite University, Berlin, Germany
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Product Name : Niagen
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 31, 2023
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Product Name : Niagen
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Product Name : Niagen
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 27, 2022
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Recipient : Sinopharm
Deal Size : Undisclosed
Deal Type : Agreement
Details : Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.
Product Name : Tru Niagen
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 06, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Recipient : Sinopharm
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
Details : Tru Niagen Immune, is a combination of ingredient Niagen (nicotinamide riboside), and Theracurmin (curcumin) is first-ever immune health supplement with a targeted NAD+ boost for the optimal maintenance and function of aging cells.
Product Name : Niagen
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 04, 2022
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A newly granted continuation patent provides additional intellectual property protection for ChromaDex’s Niagen (nicotinamide riboside) ingredient and other nicotinamide adenine dinucleotide (NAD) precursors.
Product Name : Niagen
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 16, 2022
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results of phase I clinical trial for Niagen, showed that NR supplementation significantly increased cerebral nicotinamide adenine dinucleotide levels, and resulted in altered cerebral energy metabolism and decreased levels of inflammatory cytokines in p...
Product Name : Niagen
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 03, 2022
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable